Ionis (IONS) | Financial Analysis & Statements
Ionis Pharmaceuticals Inc. Large-cap Healthcare
TL;DR: Financial Overview - Revenue, Profits & Key Metrics
Latest Quarterly: Dec 2025Income Metrics
Revenue
203.3M
Gross Profit
195.4M
96.09%
Operating Income
-214.5M
-105.48%
Net Income
-229.4M
-112.82%
Balance Sheet Metrics
Total Assets
3.5B
Total Liabilities
3.0B
Shareholders Equity
489.1M
Debt to Equity
6.20
Cash Flow Metrics
Operating Cash Flow
-126.0M
Free Cash Flow
-160.4M
Revenue & Profitability Trend
Quarter Income Flow
Dec 31, 2025
Annual Income Flow
2025
Ionis Income Statement From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 943.7M | 705.1M | 787.6M | 587.4M | 810.5M |
| Cost of Goods Sold | 15.9M | 11.2M | 9.1M | 14.1M | 10.8M |
| Gross Profit | 927.8M | 693.9M | 778.5M | 573.3M | 799.6M |
| Gross Margin % | 98.3% | 98.4% | 98.8% | 97.6% | 98.7% |
| Operating Expenses | |||||
| Research & Development | 915.6M | 901.5M | 899.6M | 833.1M | 643.5M |
| Selling, General & Administrative | 393.9M | 267.5M | 232.6M | 150.3M | 170.9M |
| Other Operating Expenses | - | - | - | - | - |
| Total Operating Expenses | 1.3B | 1.2B | 1.1B | 983.4M | 814.4M |
| Operating Income | -381.7M | -475.1M | -353.7M | -410.2M | -14.7M |
| Operating Margin % | -40.4% | -67.4% | -44.9% | -69.8% | -1.8% |
| Non-Operating Items | |||||
| Interest Income | - | - | - | - | - |
| Interest Expense | 83.8M | 84.4M | 75.6M | 2.8M | 4.4M |
| Other Non-Operating Income | 92.1M | 105.5M | 101.2M | 160.3M | -5.0M |
| Pre-tax Income | -379.6M | -460.1M | -334.0M | -258.0M | -29.1M |
| Income Tax | 1.8M | -6.2M | 32.3M | 11.7M | -551.0K |
| Effective Tax Rate % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net Income | -381.4M | -453.9M | -366.3M | -269.7M | -28.6M |
| Net Margin % | -40.4% | -64.4% | -46.5% | -45.9% | -3.5% |
| Key Metrics | |||||
| EBITDA | -381.1M | -457.8M | -322.8M | -400.7M | -9.9M |
| EPS (Basic) | $-2.38 | $-3.04 | $-2.56 | $-1.90 | $-0.20 |
| EPS (Diluted) | $-2.38 | $-3.04 | $-2.56 | $-1.90 | $-0.20 |
| Basic Shares Outstanding | 160010000 | 150000000 | 143000000 | 142000000 | 141000000 |
| Diluted Shares Outstanding | 160010000 | 150000000 | 143000000 | 142000000 | 141000000 |
Income Statement Trend
Join Our United States Telegram Channel
Get Instant Market Updates: 52-Week High/Low Alerts, Breakout Notifications & Expert Stock Analysis Delivered To Your Phone. Join Traders Making Informed Decisions Daily!
Ionis Balance Sheet From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Assets | |||||
| Current Assets | |||||
| Cash & Equivalents | 372.3M | 242.1M | 399.3M | 276.5M | 869.2M |
| Short-term Investments | 2.3B | 2.1B | 1.9B | 1.7B | 1.2B |
| Accounts Receivable | - | - | - | - | - |
| Inventory | 10.0M | 12.5M | 28.4M | 22.0M | 24.8M |
| Other Current Assets | 237.1M | 217.9M | 184.4M | 168.3M | 143.4M |
| Total Current Assets | 3.0B | 2.6B | 2.6B | 2.2B | 2.3B |
| Non-Current Assets | |||||
| Property, Plant & Equipment | 238.5M | 161.9M | 171.9M | 181.5M | 18.0M |
| Goodwill | - | - | - | - | 29.0M |
| Intangible Assets | - | - | - | - | 29.0M |
| Long-term Investments | - | - | - | - | - |
| Other Non-Current Assets | 171.6M | 127.3M | 105.3M | 75.3M | 70.6M |
| Total Non-Current Assets | 533.2M | 383.4M | 348.2M | 331.2M | 266.6M |
| Total Assets | 3.5B | 3.0B | 3.0B | 2.5B | 2.6B |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts Payable | 28.1M | 43.0M | 26.0M | 17.9M | 11.9M |
| Short-term Debt | 454.7M | 9.3M | 53.2M | 7.5M | 3.5M |
| Current Portion of Long-term Debt | - | - | - | - | - |
| Other Current Liabilities | - | - | - | - | 3.5M |
| Total Current Liabilities | 781.6M | 309.3M | 448.1M | 311.6M | 240.6M |
| Non-Current Liabilities | |||||
| Long-term Debt | 1.6B | 1.4B | 1.4B | 1.4B | 1.2B |
| Deferred Tax Liabilities | - | - | - | - | - |
| Other Non-Current Liabilities | 551.4M | 542.2M | 513.7M | - | 26.4M |
| Total Non-Current Liabilities | 2.3B | 2.1B | 2.2B | 1.6B | 1.6B |
| Total Liabilities | 3.0B | 2.4B | 2.6B | 2.0B | 1.8B |
| Equity | |||||
| Common Stock | 163.0K | 158.0K | 144.0K | 142.0K | 141.0K |
| Retained Earnings | -2.6B | -2.2B | -1.8B | -1.4B | -1.2B |
| Treasury Stock | - | - | - | - | - |
| Other Equity | - | - | - | - | - |
| Total Shareholders Equity | 489.1M | 588.4M | 386.7M | 572.9M | 771.7M |
| Key Metrics | |||||
| Total Debt | 2.1B | 1.4B | 1.5B | 1.4B | 1.3B |
| Working Capital | 2.2B | 2.3B | 2.2B | 1.9B | 2.1B |
Balance Sheet Composition
Ionis Cash Flow Statement From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | -381.4M | -453.9M | -366.3M | -269.7M | -28.6M |
| Depreciation & Amortization | 22.7M | 22.0M | 22.5M | 22.1M | 19.6M |
| Stock-Based Compensation | 133.9M | 130.2M | 105.8M | 100.3M | 120.7M |
| Working Capital Changes | -103.2M | -168.3M | -90.3M | -49.5M | -78.5M |
| Operating Cash Flow | -300.9M | -435.4M | -298.3M | -191.5M | 38.1M |
| Investing Activities | |||||
| Capital Expenditures | -51.4M | -45.3M | -23.8M | -15.7M | -12.0M |
| Acquisitions | - | - | - | - | - |
| Investment Purchases | -1.9B | -1.9B | -1.8B | -1.5B | -1.1B |
| Investment Sales | 1.7B | 1.8B | 1.6B | 989.2M | 1.3B |
| Investing Cash Flow | -272.1M | -129.0M | -209.9M | -258.3M | 200.9M |
| Financing Activities | |||||
| Share Repurchases | - | - | - | 0 | 0 |
| Dividends Paid | - | - | - | - | - |
| Debt Issuance | 770.0M | 0 | 575.0M | 0 | 632.5M |
| Debt Repayment | -267.8M | -44.7M | -488.1M | -50.7M | -318.9M |
| Financing Cash Flow | 675.8M | 433.6M | 644.1M | -55.3M | 156.2M |
| Free Cash Flow | -325.7M | -551.3M | -335.5M | -294.5M | 12.9M |
| Net Change in Cash | 102.8M | -130.8M | 135.8M | -505.0M | 395.1M |
Cash Flow Trend
Ionis Key Financial Ratios
Valuation Ratios
P/E Ratio (TTM)
-31.14
Forward P/E
-121.81
Price to Book
24.97
Price to Sales
13.09
PEG Ratio
-0.27
Profitability Ratios
Profit Margin
-40.41%
Operating Margin
-105.47%
Return on Equity
-70.80%
Return on Assets
-7.31%
Financial Health
Current Ratio
3.83
Debt to Equity
534.84
Beta
0.40
Per Share Data
EPS (TTM)
$-2.38
Book Value per Share
$3.00
Revenue per Share
$5.90
Peer Financial Comparison
| Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
|---|---|---|---|---|---|---|
| IONS | 12.2B | -31.14 | 24.97 | -70.80% | -40.41% | 534.84 |
| Vertex | 109.4B | 28.40 | 5.92 | 22.54% | 32.94% | 10.91 |
| Regeneron | 81.0B | 18.00 | 2.45 | 14.86% | 31.41% | 9.51 |
| Alnylam | 41.9B | 132.73 | 52.09 | 73.28% | 8.45% | 376.19 |
| Insmed | 31.0B | -22.40 | 40.88 | -249.28% | -210.54% | 101.43 |
| Revolution Medicines | 28.6B | -22.73 | 16.24 | -58.07% | 0.00% | 26.19 |
Financial data is updated regularly. All figures are in the company's reporting currency.






